ModifiedUnitedHealthcarePolicy CSOS4TN.S

Airway Clearance Devices (for Tennessee Only)

Medicaid and CoverKids policy for coverage and medical necessity of airway clearance devices (including HFCWO systems and other oscillation/IPV devices) for eligible beneficiaries in Tennessee.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices (for Tennessee Only)

Policy CodePolicy CSOS4TN.S

Change TypeMaterial revisions to coverage rationale and applicable codes

Effective DateApr 1, 2025

Next Review DateN/A

Key ActionComplete and document a two-month rental trial of an HFCWO system showing tolerance and efficacy before requesting ongoing coverage.

SourceLink

POLICY UPDATE CHANGES

Coverage Rationale: Added language that combination CPEP, CHFO, and nebulized medication therapy devices for oscillation and expansion (OLE) are considered unproven and not medically necessary.

Applicable Codes: Added HCPCS codes A7021 and E0469.

Applicable Codes: Revised description for HCPCS code E0483.

Updated Clinical Evidence and References sections to reflect the most current information.

2-monthinitial trial period required for HFCWO

state-specificapplies to Tennessee Medicaid and CoverKids

codes listedHCPCS and ICD-10 codes provided

CPEP/CHFO/IPVDevices now considered not medically necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

04/01/2025Policy revision date

Devices Considered Not Medically Necessary

Devices considered not medically necessary (unproven):

Combination continuous positive expiratory pressure (CPEP); continuous high frequency oscillation (CHFO); and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary due to insufficient quality evidence or consistency of findings.

Intrapulmonary percussive ventilation (IPV) devices for home use are considered unproven and not medically necessary; there is insufficient quality evidence to support long-term home use.

Combination CPEP, CHFO, and nebulized medication therapy devices for OLE lack adequately powered, well-designed randomized controlled trials demonstrating safety and clinical efficacy for ongoing/home use; therefore continued coverage is not supported.

Evidence summaries note limited and heterogeneous studies (including small retrospective series, pilot studies, and systematic reviews) that do not provide consistent demonstration of reduced ICU length of stay, improved gas exchange, or sustained clinical benefit to support routine or long-term home use of IPV or combined OLE devices.

Medical Necessity Details

HFCWO Medical Necessity Criteria

Coverage for HFCWO devices requires:

Diagnosis: Documented diagnosis of cystic fibrosis, bronchiectasis, or neuromuscular disease

See Applicable Codes list for examples

Trial of therapy: Completion of a two-month rental trial demonstrating individual tolerance and efficacy2 months

Ongoing medical necessity contingent on trial results

HFCWO contextual considerations

Evidence summaries suggest potential roles in select populations but do not provide definitive, prescriptive medical necessity criteria in this excerpt.

Applicable Codes and Key Coding Details

Applicable HCPCS/Healthcare Procedure CodesHCPCS

A7021	Supplies and accessories for lung expansion airway clearance , continuous high frequency oscillation, and nebulization device handset; nebulizer kit; biofilter
A7025	High frequency chest wall oscillation system vest, replacement for use with patient- owned equipment; each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient- owned equipment; each
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
E0481	Intrapulmonary percussive ventilation system and related accessories
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each

Applicable ICD-10 Diagnosis Codes (selected examples)ICD-10

E84.0	Cystic fibrosis with pulmonary manifestations
J47.9	Bronchiectasis, uncomplicated
J47.1	Bronchiectasis with (acute) exacerbation
G12.21	Amyotrophic lateral sclerosis
G12.0	Infantile spinal muscular atrophy, type [Werdnig-Hoffman]
G71.00	Muscular dystrophy, unspecified
G35	Multiple sclerosis

Applicable HCPCS Codes (documented changes)HCPCS

A7021	HCPCS code added to Applicable Codes
E0469	HCPCS code added to Applicable Codes
E0483	HCPCS code description revised

HFCWO trial duration — 2 months

HFCWO initial rental trialTwo-month rental trial required to confirm individual tolerance and efficacy before ongoing coverage

Purpose of trialEstablish ongoing medical necessity for covered indications (neuromuscular disease, bronchiectasis, cystic fibrosis)

Step-therapy roleInitial rental trial functions as a step prior to approval for continued provision

Peak cough flow — < 270 L/min

Peak cough flow thresholdPeak cough flow < 270 L/min

Clinical use

Provider Requirements and Operational Guidance

Step Therapy

Rental trial as step

An initial two-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is required to establish individual tolerance and clinical efficacy before ongoing provision of HFCWO equipment will be considered. Failure to document completion of the required two-month rental trial demonstrating benefit and tolerability may result in denial of ongoing equipment coverage.

Rental trial duration: 2 months (required prior to approval for ongoing HFCWO provision).
Rental trial functions as a step prior to long-term coverage — documentation of adherence, symptom response, and any adverse effects during the trial must be submitted.

Denial Risk

Unproven device types

Requests for combination devices (CPEP/CHFO with nebulized therapy) or for home-use intrapulmonary percussive ventilation (IPV) are considered unproven and not medically necessary. Such requests should be carefully evaluated and will typically be denied in the absence of robust supporting clinical evidence.

Rental and Purchase Rules for Devices

Equipment	Rental / Purchase Rule	Notes
High-frequency chest wall oscillation (HFCWO) systems (vest systems, hoses, supplies)
rental
Initial provision via a two-month rental trial; ongoing provision or purchase contingent on demonstration of individual tolerance and efficacy during the trial

Equipment	Rental / Purchase Rule	Notes
High-frequency chest wall oscillation (HFCWO), intrapulmonary percussive ventilation (IPV), and oscillation & lung expansion (OLE) combination devices (CPEP/CHFO with nebulized therapy)
rental \| purchase \| capped_rental
Policy revision notes: combination OLE devices are designated unproven and not medically necessary; HCPCS coding updates (A7021, E0469 added; E0483 description revised) may affect billing and authorization pathways

Required Documentation for Coverage

Note

Devices and Uses Not Covered

UnitedHealthcare does not cover CPEP/CHFO/OLE devices or home-use IPV devices; these device types are considered unproven and not medically necessary and therefore are listed under the policy’s not-covered exclusions.

The policy’s not-covered section reiterates that combination CPEP/CHFO/nebulized OLE devices are unproven and not medically necessary, and that there is insufficient evidence to support long-term home use of IPV; these positions may result in denial of coverage for those device requests.

Combination CPEP/CHFO/nebulized OLE devices are explicitly listed as not covered because of insufficient or inconsistent evidence; similarly, the policy does not support home provision of IPV due to limited quality data.

Requests for combined CPEP, CHFO, and nebulized medication OLE devices are classified as unproven and not medically necessary and are therefore included in the policy’s not-covered list.

Definitions and Background

Airway clearance can be inadequate in disorders such as cystic fibrosis, bronchiectasis, and neuromuscular diseases, which may prompt consideration of device-based therapies. The policy distinguishes between device types: HFCWO may be covered for specified diagnoses after an evidenced two-month rental trial, whereas combination CPEP/CHFO/OLE devices and home-use IPV lack sufficient evidence and are considered unproven and not medically necessary.

Bronchiectasis

DefinitionChronic respiratory disease characterized by dilation (ectasia) of the airways or bronchi associated with recurrent, chronic, or refractory infections

Clinical manifestationsClinically significant bronchiectasis typically includes frequent cough, sputum production most days, and a history of exacerbations

Diagnostic notePresence of bronchiectasis should be supported by clinical symptoms such as cough most days and sputum production most days

HFCWO — High-frequency chest wall oscillation

Replacement and General DME Notes

General DME

Policy purposeGeneral durable medical equipment guidance for interpretation of benefit plan coverage; reference federal, state, or contractual requirements

Coding referenceApplicable HCPCS codes for airway clearance and HFCWO equipment include E0483, E0481, E0469 and supply codes A7021, A7025, A7026

Coverage notePlan-specific terms govern; UnitedHealthcare may modify policies and use third-party tools (e.g., InterQual) to assist administration

Policy Revision History

2025-04-01policy_revisionLatest

Added coverage rationale stating combination CPEP/CHFO/nebulized medication therapy (OLE) devices are considered unproven and not medically necessary; added HCPCS codes A7021 and E0469; and revised the description for HCPCS code E0483.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices (for Tennessee Only)

Policy CodePolicy CSOS4TN.S

Change TypeMaterial revisions to coverage rationale and applicable codes

Effective DateApr 1, 2025

Next Review DateN/A

Key ActionComplete and document a two-month rental trial of an HFCWO system showing tolerance and efficacy before requesting ongoing coverage.

SourceLink

On This Page

HFCWO potential appropriate contexts (evidence-based supportive mentions): Studies report reductions in hospitalizations, improved adherence, and some lung function or quality-of-life improvements in select small trials or observational cohorts for patients with neuromuscular disease, bronchiectasis, or chronic hypersecretive disease, but limitations (small size, lack of controls) are frequent.

Neuromuscular disease airway clearance

Guidance for neuromuscular patients from ATS

ATS-assisted cough recommendation: Use assisted cough technologies in patients whose history or objective testing suggests difficulty clearing secretions, specifically when peak cough flow is less than 270 L/min or maximal expiratory pressure is less than 60 cm H2O.peak cough flow < 270 L/min; MEP < 60 cm H2O

Committee strongly supports mechanical insufflation-exsufflation in patients with DMD.

Used to identify patients with difficulty in airway clearance who may benefit from assisted cough technologies

Source guidanceRecommendation cited from ATS committee guidance

Maximal expiratory pressure (MEP) — < 60 cm H2O

Maximal expiratory pressure (MEP) thresholdMEP < 60 cm H2O

Clinical implicationThreshold supports use of assisted cough technologies in patients with inadequate expiratory force

Guideline sourceRecommendation cited from ATS committee guidance

Unproven device types: Combination continuous positive expiratory pressure (CPEP), continuous high frequency oscillation (CHFO), and nebulized medication therapy devices for oscillation and lung expansion (OLE).

Unproven device types: Intrapulmonary percussive ventilation (IPV) devices for home use.

Denial Risk

Denial triggers for unproven devices

Devices or device combinations determined to be unproven and not medically necessary (for example, combination CPEP/CHFO/nebulized OLE devices or home-use IPV) are denial triggers. Claims for these devices may be denied unless convincing, contemporaneous clinical documentation justifies an exception under applicable federal, state, or contractual requirements.

Denial triggers: Combination CPEP, CHFO, and nebulized medication therapy devices for OLE.
Denial triggers: Intrapulmonary percussive ventilation (IPV) for long-term home use.

Documentation Required

Required documentation for HFCWO coverage

Coverage of HFCWO requires documentation that supports the beneficiary meets clinical criteria for a covered indication and that necessary prior steps have been completed. Providers must submit contemporaneous clinical records demonstrating diagnosis, prior therapies tried, and objective response during the required rental trial.

Required documentation: Clinical diagnosis supporting one of the covered conditions (e.g., neuromuscular disease, bronchiectasis, cystic fibrosis).
Required documentation: Evidence of prior airway clearance interventions attempted and rationale for HFCWO.
Required documentation: Detailed rental trial documentation (dates of rental, adherence, subjective and objective response, any adverse events).
Required documentation: Any additional InterQual or payer-requested assessments used to determine ongoing medical necessity.

Billing Rule

Applicable Codes Updated

Applicable HCPCS codes have been updated for provider reference. Inclusion of a code in this policy does not guarantee coverage; verify federal, state, or contractual benefit requirements and submit appropriate documentation with claims.

Applicable Codes Added/Revised: HCPCS A7021 and E0469 were added; description for E0483 was revised.
Examples of listed codes: A7021, A7025, A7026, E0469, E0481, E0483.

DefinitionHigh-frequency chest wall oscillation (HFCWO): external chest wall oscillation delivered by devices such as The Vest to mobilize airway secretions

Typical devicesWearable inflatable vest systems delivering rapid chest wall oscillation with associated hoses and supplies (HCPCS E0483, A7025, A7026)

Intended usePromote airway clearance and bronchial drainage when external chest manipulation is the physician's treatment of choice

OLE — Oscillation and lung expansion (combination devices)

DefinitionOscillation and lung expansion (OLE): combination approaches including CPEP, CHFO, and nebulized medication therapy intended to provide oscillation and lung expansion for airway clearance or perioperative pulmonary complication reduction

Clinical contextStudied perioperatively to reduce postoperative pulmonary complications in high-risk surgical patients (Huynh et al.)

Coverage stanceCombination OLE devices are considered unproven and not medically necessary due to insufficient quality evidence

IPV — Intrapulmonary percussive ventilation

DefinitionIntrapulmonary percussive ventilation (IPV): delivery of small, rapid bursts of gas (percussive breaths) to achieve intrapulmonary percussion for secretion mobilization

Evidence summarySystematic reviews and small studies provide weak or inconsistent evidence for IPV effectiveness; long-term home use is not supported by high-quality evidence

Typical settingFeasibility and safety studies often conducted in ICU or inpatient settings rather than long‑term home use

HFCWO — High-frequency chest wall compression (HFCWO) devices

DefinitionHigh-frequency chest wall compression (HFCWO) devices: external devices designed to promote airway clearance and bronchial drainage when external chest manipulation is the physician's treatment of choice

ComponentsIncludes wearable vests and associated accessories and supplies (see applicable HCPCS codes)

Clinical roleUsed to enhance mucus transport and mobilize secretions in appropriate patients

OLE / combination CPEP/CHFO

DefinitionOLE / combination CPEP/CHFO: combined oscillation and lung expansion therapies that pair continuous positive expiratory pressure (CPEP) or continuous high frequency oscillation (CHFO) with nebulized medication therapy

Intended effectIntended to reduce postoperative pulmonary complications and support airway clearance in selected contexts

Policy stanceThese combination devices are considered unproven and not medically necessary for routine coverage

IPV — Intrapulmonary percussive ventilation (IPV)

DefinitionIntrapulmonary percussive ventilation (IPV): device-based airway clearance therapy delivering percussive breaths to augment secretion clearance

Evidence limitationsEvidence is limited by small numbers, heterogenous methods, and weak support for reductions in ICU length of stay or other consistent clinical benefits

Coverage implicationLong-term home use of IPV is considered unsupported by sufficient quality evidence and may be denied